Nonapeptide-1 158563-45-2

99% up by HPLC

Product categories

New Products

Product Details

Product Information

Product name	Nonapeptide-1
CAS No.	158563-45-2
Molecular Formula	C61H87N15O9S
Molecular Weight	1206.50
Quality Standard	99% up by HPLC
Appearance	White powder

COA of Nonapeptide-1

TEST	SPECIFICATION	RESULTS
Appearance	White powder	Complies
Identification	IR	Complies
	HPLC	Complies
Heavy metal	≤10ppm	5ppm
Pb	≤3ppm	1.5ppm
Hg	≤0.1ppm	0.05ppm
Cd	≤1ppm	0.2ppm
Loss on drying	≤0.5%	0.12
Residue on lgnition	≤0.1%	0.03
Single impurity	≤0.5%	0.12
Total impurity	≤1.0%	0.29
Total bacteria	≤1000cfu/g	<1000
Yeast and Mould	≤100 cfu/g	<000
E.coli/25g	Absent	Absent
Salmonella/25g	Absent	Absent
Assay	≥99.0%	99.4%
Conclusion	Conforms with USP/EP standards

Usage

Function of Nonapeptide-1

Nonapeptide-1, also called Melanostatine™ 5, is a propriety peptide that was originally developed for its antimicrobial activities. Animal research has revealed, however, that nonapeptide-1 can inhibit the synthesis of melanin, which makes it of interest for treating certain skin conditions. Animal models suggest that nonapeptide-1 can reduce synthesis of melanin and help decrease skin pigmentation to a substantial degree.

Nonapeptide-1 was first isolated from the yeast Streptomyces clavifer, but is now produced synthetically through recombinant genetic technology. It was first developed for its antimicrobial activities, but has since been found to be a strong inhibitor of melanin formation laboratory studies of yeast and melanoma (skin cancer) cells . Nonapeptide-1 consists of the amino acids arginine-lysine-methionine-phenylalanine-proline-tryptophan-valine.

Research in fungi indicates that nonapeptide-1, at a concentration of 200 ug/mL, is capable of fully inhibiting the synthesis of melanin2. Fungi are used in this particular research because they more closely approximate conditions in human cells, but require fewer resources than animal models. Research in animal models indicates that nonapeptide-1 may effectively reduce pigmentation, after just one application, for up to 28 days at a timev[5]. At 100 micromolar concentration, nonapeptide-1 can inhibit 25-35% of tyrosinase activity in animal models and can reduce the melanin content of melanocytes by 27-43%.

Nonapeptide-1 is of primary research interest for its ability to reduce hyperpigmentation by inhibiting the action of tyrosinase in melanin-producing cells. The ability to regulate melanin production has potential application in a number of conditions, including photodamage of the skin.

Research also suggests that nonapeptide-1 may play a role in the central nervous system where it may act on both dopaminergic receptors and opioid receptors to modify pain signaling as well as behavior. Studies in mice support the idea that nonapeptide-1 may have central actions that affect behavior and pain.

Hot Tags : custom polypeptide polypeptide supplier nonapeptide-1 158563-45-2 polypeptide polypeptide synthesis

Send A Message

Related Products

LIRAGLUTIDE 204656-20-2

Product Information Product name Liraglutide Sequence H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu- Glu-Gly-Gln-Ala-Ala-Lys[N6-[N-(1-oxohexadecyl)-L-γ-glutamyl]- -Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH CAS No. 204656-20-2 Molecular Formula C172H265N43O51 Molecular Weight 3751.20 Storage 2~8℃ Appearance White to off-white crystalline powder COA of Liraglutide Test Specification Results Appearance: White to off-white crystalline powder or lumps White powder Identity: 3751.2±1.0 3751.1 Purity (By HPLC) : Not Less than 98.0%; 99.51% Residual solvents: ≤0.25%total; ≤0.1%individual; ≤0.01%CH2CN Complies Related Peptide Total Impurity ≤ 2.0% Largest Single Impurity ≤ 1.0% TI =0.41% LSI =0.25% Peptide Content: Not Less than 85.0% 87.7% Water (K.F.): Not more than 5% 4.2% Acetate acid: Not more than 10% 8.1% Bacterial Endotoxins Not more than 50IU/mg Complies Usage Function and Usage of Liraglutide 204656-20-2 1、 Type 2 diabetes Liraglutide improves control of blood glucose.It reduces meal-related hyperglycemia (for 24 hours after administration) by increasing insulin secretion (only) when required by increasing glucose levels, delaying gastric emptying, and suppressing prandial glucagon secretion. In common to various degrees with other GLP-1 receptor agonists, liraglutide has advantages over more traditional therapies for type 2 diabetes: · Liraglutide acts in a glucose-dependent manner, meaning it will stimulate insulin secretion only when blood glucose levels are higher than normal, preventing "overshoot". Consequently, it shows negligible risk of hypoglycemia. · Liraglutide has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies). · Liraglutide decreases appetite and inhibits body weight gain, as shown in a head-to-head study versus glimepiride. · Liraglutide lowers blood triglyceride levels. 2、Obesity Liraglutide has been approved as an injectable adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients. The specified criteria are an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight), in the presence of at least one weight-related comorbid condition (e.g.hypertension, type 2 diabetes mellitus, or dyslipidemia). In late 2014, data were reported from the SCALE™ Obesity and Prediabetes trial, which is a randomised, double-blind, placebo-controlled, multinational trial in non-diabetic people with obesity and non-diabetic people who are overweight with comorbidities. In this phase 3a trial, there were 3,731 participants randomised to treatment with liraglutide 3 mg or placebo, both in combination with diet and exercise. Those who completed the 56-week trial achieved an average weight loss of 9.2%, to be compared with a 3.5% reduction in the placebo group.